ISR
$2.72
Isoray
$.31
12.86%
ISR
Earnings Whisper ®
N/A
2nd Quarter December 2020
Consensus:  ($0.01)
Revenue:  $2.40 Mil
Tuesday
Feb 9
4:05 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when ISR reports earnings?
Beat
Meet
Miss

Where is ISR's stock price going from here?
Up
Flat
Down
Stock chart of ISR
Analysts
Summary of analysts' recommendations for ISR
Score
Grade
Pivots
Resistance
$3.29
$2.98
$2.69

$2.38

Support
$2.09
$1.78
$1.49
Tweet
Growth
Description
IsoRay, Inc. is a medical technology company that produces therapeutic radioactive isotopes. Through its subsidiary, IsoRay Medical, Inc., develops, manufactures and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases. The Company is engaged in the production and sales of Cesium-131 (Cs-131) brachytherapy seeds. Brachytherapy seeds are small devices containing a therapeutic dose of radiation used in an interstitial radiation procedure. The brachytherapy procedure places radioactive seeds as close as possible to (in or near) the cancerous tumor. The Cs-131 includes radioisotope in the treatment of all malignant tumors, such as prostate cancer, brain cancer, breast cancer, colorectal cancer, gynecological cancer, lung cancer, liver cancer, ocular melanoma and pancreatic cancer. The Company's Proxcelan Cesium-131 seed is classified as a Class II device. The Company competes with Varian Medical Systems, Siemens Healthcare, Elekta AB and Accuray Incorporated.